Endovascular embolization of brain arteriovenous malformations with Eudragit-E

Area of Science:

• Interventional Neurology
• Vascular Neurosurgery
• Biomaterials Science

Background:

• Eudragit-E, a liquid embolic agent, has been used for brain arteriovenous malformation (AVM) embolization but lacks extensive safety and feasibility documentation.
• This study reports on the clinical experience with Eudragit-E for treating human brain AVMs.

Observation:

• Thirty endovascular procedures using Eudragit-E were performed on 22 patients (14 men, 8 women; mean age 41.1 years) between June 1998 and February 2014.
• The mean follow-up period was 56 months, with Spetzler-Martin grades ranging from I to IV.
• Complete obliteration with embolization alone was 27.3%, and the overall obliteration rate, including subsequent treatments, was 72.7%.

Findings:

• Eudragit-E embolization resulted in an overall AVM obliteration rate of 72.7% when combined with other therapies.
• Directly related embolization complications occurred in 10.0% of cases, including two cerebral infarctions and one intracerebral hemorrhage.
• The safety and effectiveness of Eudragit-E for brain AVM treatment were deemed satisfactory.

Implications:

• Eudragit-E demonstrates acceptable safety and efficacy for endovascular embolization of brain AVMs.
• Further research may elucidate optimal patient selection and procedural techniques for maximizing outcomes.
• This experience contributes to the understanding of Eudragit-E's role in neurovascular interventions.